55
Participants
Start Date
December 31, 2006
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
RAD001
RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
Sorafenib
A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
The Methodist Hospital Research Institute, Houston
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
The Methodist Hospital Research Institute
OTHER